L-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-? levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
MetadataShow full item record
Considering the pathologic importance of metabolic disturbances, advanced glycation end products (AGEs), and chronic inflammation in diabetes mellitus and ameliorating potentials of L-carnosine in hampering these detritions and because these effects have not been investigated in patients with type 2 diabetes (T2D) so far, we conducted the current study. We hypothesized that L-carnosine would improve glycemic control, lipid profile, AGE, soluble receptor of AGEs (sRAGE), and inflammatory markers. In a randomized, double-blind, placebo-controlled clinical trial, 54 patients with T2D were recruited and assigned into either intervention group (n = 27, receiving 2 capsules of L-carnosine 500 mg each) or control group (n = 27). Blood samples and dietary intakes information were collected at baseline and after 12 weeks of intervention. L-Carnosine supplementation resulted in significant decrease in fat mass and an increase in fat-free mass in the intervention group compared with the placebo group (1.5% and 1.7%, respectively) (P <.05). A significant reduction in fasting blood glucose (13.1 mg/dL); glycated hemoglobin (.6%); and serum levels of triglycerides (29.8 mg/dL), carboxymethyl lysine (91.8 ng/mL), and tumor necrosis factor-? was detected in the L-carnosine group compared with the placebo group (P <.05). In the L-carnosine group, a significant reduction in serum pentosidine levels (2.8 ng/mL) was observed compared with those at baseline (P <.05). No significant differences were observed in dietary intake, body mass index, systolic and diastolic blood pressure, fasting insulin levels, homeostasis model assessment of insulin resistance and secretion, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, sRAGE, interleukin (IL)-6, and IL-1? levels between the groups after adjusting for baseline values and covariates (P >.05). Collectively, L-carnosine lowered fasting glucose, serum levels of triglycerides, AGEs, and tumor necrosis factor-? without changing sRAGE, IL-6, and IL-1? levels in T2D patients. é 2017 Elsevier Inc.
Showing items related by title, author, creator and subject.
Salehpoor, F; Meshkini, A; Razmgiri, A; Mahdkhah, A (2016)Objective: The aim of the study was to systematically review which factor of serum, assessed in traumatic brain injury (TBI), predicts patient's outcome. Materials and Methods: Databases were searched for relevant publications ...
Ghergherehchi, R; Habibzadeh, A (2015)Iron overload is a common finding in chronically transfused ?-thalassemia major (?-TM) patients with possible effect on ? cell function and insulin resistance. In this study we aimed to evaluate glucose metabolism, insulin ...
Reproductive hormonal changes following two types of hypocaloric diets in overweight and obese polycystic ovary syndrome women Hamayeli Mehrabani, H; Tahbaz, F; Salehpour, S; Hedayati, M; Amiri, Z; Ghassemi, A (2010)Introduction: The appropriate combination and composition of hypocaloric diets for obese women with polycystic ovary syndrome (PCOS) is still unclear. The aim of this study was to investigate the effects of a high protein-low ...